论文部分内容阅读
近年来,随着对载脂蛋白(APO)及高密度脂蛋白(HDL)研究的不断深入,人们发现载脂蛋白功能异常是导致脂质代谢紊乱的主要原因。本研究旨在对ICVD患者血清HDL-ch、APOA—Ⅰ、A-Ⅱ及APOB水平进行初步观察,探讨其中的规律,为揭示ICVD的发病机理及其防治提供可行的线索。 资料与方法 病例组 97例,其中男67例,年龄40～82岁,平均62.5岁。女30例,年龄44～74岁,平均62.1岁。全部患者均经详细询问病史和全面检查,并经CT证实,且排除了心肌梗塞、肝肾病变、糖尿病以及近期曾服用过影响脂蛋白代谢药物者。 根据患者的病程分为急性期(发病4周内),其
In recent years, with the continuous research on apolipoproteins (APO) and high density lipoprotein (HDL), it has been found that the dysfunction of apolipoproteins is the main reason leading to disorder of lipid metabolism. The purpose of this study is to investigate the serum levels of HDL-ch, APOA-Ⅰ, A-Ⅱ and APOB in ICVD patients and to explore the rules therein, so as to provide feasible clues for revealing the pathogenesis and prevention and treatment of ICVD. Materials and Methods 97 cases of cases, including 67 males, aged 40 to 82 years, mean 62.5 years. Female 30 cases, aged 44 to 74 years, an average of 62.1 years old. All patients were asked about their medical history and a comprehensive examination, and confirmed by CT, and ruled out myocardial infarction, liver and kidney disease, diabetes and those who have been taking the impact of lipoprotein metabolism drugs. According to the duration of the patient is divided into acute (within 4 weeks of onset), its